Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND1 | P24385 | 16/20 | 1.00 |
| ▸ | CDK4 | P11802 | 13/20 | 1.00 |
| ▸ | CDK6 | Q00534 | 11/20 | 0.75 |
| ▸ | CDK1 | P06493 | 2/20 | 0.57 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.57 |
| ▸ | CCND3 | P30281 | 2/20 | 0.57 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.57 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.57 |
| ▸ | CDK2 | P24941 | 1/20 | 0.57 |
| ▸ | CDK7 | P50613 | 1/20 | 0.57 |
| ▸ | CDK9 | P50750 | 1/20 | 0.57 |
| ▸ | CCNH | P51946 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24322347 | 0.91 | CCND1 (0.84) | CCND1CDK4CDK6CCNA2CCND3 | |
| SCHEMBL29514918 | 0.91 | CCND1 (0.84) | CCND1CDK4CDK6CCNA2CCND3 | |
| SCHEMBL29515081 | 0.88 | CCND1 (0.79) | CCND1CDK4CDK6 | |
| SCHEMBL25235418 | 0.88 | CCND1 (0.79) | CCND1CDK4CDK6 | |
| SCHEMBL29515132 | 0.88 | CCND1 (0.79) | CCND1CDK4CDK6 | |
| SCHEMBL25285212 | 0.88 | CCND1 (0.79) | CCND1CDK4CDK6 | |
| SCHEMBL25283162 | 0.88 | CCND1 (0.78) | CCND1CDK4CDK6CDK1CCNA2 | |
| SCHEMBL29514949 | 0.88 | CCND1 (0.78) | CCND1CDK4CDK6 | |
| SCHEMBL25284787 | 0.86 | CCND1 (0.76) | CCND1CDK4CDK6CCNA2CCND3 | |
| SCHEMBL29514856 | 0.86 | CCND1 (0.76) | CCND1CDK4CDK6CCNA2CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116583283-A | CDK inhibitors and their use as pharmaceuticals | 普莱鲁德疗法有限公司 | 2023-08-11 | — | — | CN | claimed |
| EP-4214213-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | Prelude Therapeutics, Incorporated (US) | 2023-07-26 | — | — | EP | claimed |
| WO-2022061273-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2022-03-24 | — | — | WO | claimed |
| CN-116583283-A | CDK inhibitors and their use as pharmaceuticals | 普莱鲁德疗法有限公司 | 2023-08-11 | — | — | CN | disclosed |
| EP-4214213-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | Prelude Therapeutics, Incorporated (US) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022061273-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2022-03-24 | — | — | WO | disclosed |